Biotech and pharma teams are increasingly turning to strategic outsourcing to capture more value from mature products as patent cliffs loom and internal resources face pressure. An analysis highlights that mature brands often contribute 20% to 40% of annual revenue for major companies, but legacy operating models may not fit today’s cost and portfolio realities. The report argues that late-lifecycle assets require different commercialization and compliance approaches—such as lowering marketing spend, reducing headcount, centralizing operations, and outsourcing regulatory, safety, and quality functions. It cites Cencora’s Kirsten Jacobs, noting that late-cycle commercialization can rely on lower marketing and leaner operational footprints. For industry readers, the immediate takeaway is that operational restructuring is becoming a visible lever in mature-product strategy, potentially shaping vendor selection, regulatory staffing models, and cost structures across pharma portfolios.